December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Equillium, Inc. - Common Stock (NQ:EQ)

2.950 +0.110 (+3.87%)
Streaming Delayed Price Updated: 3:46 PM EDT, May 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Equillium, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Equillium Announces Three Poster Presentations at the Annual Meeting of The American Association of Immunologists
From Equillium, Inc.
Via Business Wire
News headline image
Equillium Announces Three Poster Presentations at the Transplantation & Cellular Meetings of the ASTCT and CIBMTR
From Equillium, Inc.
Via Business Wire
News headline image
Equillium Announces Oral Presentation at the Italian Society of Experimental Hematology
From Equillium, Inc.
Via Business Wire
News headline image
Equillium Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate & Clinical Development Updates
From Equillium, Inc.
Via Business Wire
News headline image
Equillium Announces Two Oral Presentations at the Annual Meeting of the European Society for Blood and Marrow Transplantation
From Equillium, Inc.
Via Business Wire
News headline image
Equillium's Itolizumab Shows Durable Clinical Response In GvHD Patients ↗
Equillium Inc (NASDAQ: EQ) announced two oral presentations on itolizumab at the Annual Meeting of the European Society for Blood and Marrow Transplantation.  
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
Thursday saw 34 companies set new 52-week lows. Facts of Interest About Today's 52-Week Lows: SecureWorks (NASDAQ:SCWX) was the largest company by market cap to... 
Via Benzinga
News headline image
Equillium Adds Three Drugs To Its Pipeline Via Bioniz Acquisition ↗
Equillium Inc (NASDAQ: EQ), with only one asset in its pipeline, is expanding its drug development efforts via the acquisition of Bioniz Therapeutics. The deal,... 
Via Benzinga
News headline image
Equillium Acquires Bioniz Therapeutics Significantly Expanding Pipeline of Novel Immunomodulatory Drug Candidates
From Equillium, Inc.
Via Business Wire
News headline image
Equillium Provides Timing Update on Conference Presentations
From Equillium, Inc.
Via Business Wire
News headline image
Equillium to Present at the SVB Leerink Virtual Global Healthcare Conference
From Equillium, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
Gainers Mustang Bio (NASDAQ:MBIO) shares ... 
Via Benzinga
News headline image
Equillium Announces Multiple Abstracts Accepted for Presentation at the Transplantation & Cellular Meetings of ASTCT and CIBMTR
From Equillium, Inc.
Via Business Wire
News headline image
Equillium to Present at the H.C. Wainwright Virtual BioConnect Conference
From Equillium, Inc.
Via Business Wire
News headline image
10 Biggest Price Target Changes For Wednesday ↗
UBS cut the price target for Adobe Inc. (NASDAQ: ADBE) from $635 to $575. Adobe shares fell 2.3% to $541.06 in pre-market trading. SVB Leerink lowered the price target on... 
Via Benzinga
News headline image
45 Biggest Movers From Yesterday ↗
Gainers ATA Creativity Global (NASDAQ: AACG) gained 114.3% to close at $2.55. Hoth Therapeutics, Inc. (NASDAQ: HOTH) surged 85.7% to settle at $1.30 after the company announced... 
Via Benzinga
News headline image
Equillium Announces Publication of Data in the Journal of Clinical Investigation Highlighting the Importance of the CD6-ALCAM Pathway in the Pathogenesis of Lupus Nephritis
From Equillium, Inc.
Via Business Wire
News headline image
Equillium To Reassess Potential For Its Asthma Trials ↗
Equillium Inc's (NASDAQ: EQ) Phase 1b EQUIP study of itolizumab in patients with uncontrolled asthma met its primary objective. The data demonstrated an on-target... 
Via Benzinga
News headline image
Equillium Announces Data from Phase 1b EQUIP Study in Patients with Uncontrolled Asthma
From Equillium, Inc.
Via Business Wire
News headline image
Equillium Announces Additional Patient Data at ASH 2021 Demonstrating Continued Positive and Durable Clinical Responses in Acute Graft-Versus-Host Disease Patients Treated with Itolizumab
From Equillium, Inc.
Via Business Wire
News headline image
Equillium Reports Third Quarter 2021 Financial Results and Provides Clinical Development Updates
From Equillium, Inc.
Via Business Wire
News headline image
Equillium to Present at Two Upcoming Investor Conferences
From Equillium, Inc.
Via Business Wire
News headline image
Equillium Presents Clinical Data from EQUALISE Phase 1b Study in Lupus Patients at the American Society of Nephrology Annual Meeting
From Equillium, Inc.
Via Business Wire
News headline image
Equillium Presents Interim Safety Data from First Cohort of Asthma Patients in Phase 1b EQUIP Study at the American College of Allergy, Asthma & Immunology Meeting
From Equillium, Inc.
Via Business Wire
News headline image
Equillium Announces Two Abstracts Accepted for Presentation at the 63rd ASH Annual Meeting and Exposition
From Equillium, Inc.
Via Business Wire
News headline image
Equillium Reveals Early Safety Data For Itolizumab In Lupus Patients ↗
Equillium Inc (NASDAQ: EQ) announced interim data from the Type A portion of the Phase 1b EQUALISE study in systemic lupus erythematosus (SLE) patients. Data were... 
Via Benzinga
News headline image
Equillium Announces Interim Safety Data and Reduction in Proteinuria for Lupus Patients Treated with Itolizumab in the EQUALISE Study Presented at the ACR Annual Meeting
From Equillium, Inc.
Via Business Wire
News headline image
Equillium Announces Two Abstracts Accepted for Presentation at the Upcoming Virtual 2021 American Society of Nephrology Annual Meeting
From Equillium, Inc.
Via Business Wire
News headline image
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
News headline image
Equillium Announces Multiple Abstracts Accepted for Presentation at ACR Convergence 2021
From Equillium, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.